{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.98","upperLimit":"23.78","value":"16.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"144"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with confirmed objective tumor response, CR or PR, as determined by investigator using modified RECIST criteria. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to l\\< 10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered atezolizumab intravenously on Day 1 of each 21 day cycle at a fixed dose of 1200 mg. Atezolizumab treatment were to continued as long as participants were experiencing clinical benefit as assessed by the investigator.","id":"OG000","title":"Atezolizumab"}],"paramType":"NUMBER","populationDescription":"ITT population for efficacy analyses included all randomized participants, regardless of whether they received any study drug. In the efficacy analyses, the ITT population, participants were grouped according to the treatment arm to which they were assigned. The data was planned to be reported for Atezolizumab arm only","reportingStatus":"POSTED","timeFrame":"From the time of randomization to the date of death due to any cause or up to data cut off date: 08 May 2015 (up to 21 months)","title":"ORR (Modified RECIST)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}